NGM282 safely reduces bile acid, fibrosis markers in PSC

NGM282 inhibited bile acid synthesis and decreased fibrosis markers without significantly affecting alkaline phosphatase levels among patients with primary sclerosing cholangitis, according to data published in Journal of Hepatology.
“Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by strictures of the biliary tree for which there is presently a dearth of effective medical treatment,” Gideon M. Hirschfield, MD, PhD, from the Birmingham Biomedical Research Center in the United Kingdom, and colleagues wrote. “The current trial confirms the clinical

Source link

Related posts

VIDEO: GS-9674 demonstrates safety, efficacy for PSC


What causes malabsorption?


Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy